Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio Inc (GRI) is a clinical-stage biotechnology pioneer advancing novel NKT cell-targeted therapies for inflammatory and autoimmune disorders. This dedicated news hub provides investors and industry stakeholders with essential updates on therapeutic developments, financial disclosures, and strategic milestones.
Access timely reports on GRI-0621 (oral inhibitor for liver disease/dermatology) and GRI-0803 (autoimmune candidate), including clinical trial progress, regulatory filings, and peer-reviewed research. Our curated collection features press releases, earnings call transcripts, and partnership announcements directly from the company and verified sources.
Key coverage areas include phase trial results, intellectual property updates, executive leadership changes, and scientific conference presentations. Bookmark this page to monitor GRI Bio's progress in developing oral therapies that modulate immune responses through its proprietary NKT cell platform.
GRI Bio (NASDAQ: GRI) has strengthened its intellectual property portfolio with two significant patent grants in Europe and Japan. The European patent covers GRI-0803, a novel activator of type 2 diverse NKT cells being developed for autoimmune disorders, particularly systemic lupus erythematosus. The Japanese patent focuses on methods for modulating dNKT and iNKT cells in treating inflammatory conditions through Retinoic Acid Receptor agonists.
The company's lead program, GRI-0621, is currently in a Phase 2a clinical trial for idiopathic pulmonary fibrosis (IPF). Interim data is expected in Q2 2025, with topline results anticipated in Q3 2025. The study is designed as a randomized, double-blind, multi-center, placebo-controlled trial.
GRI Bio (NASDAQ: GRI) announced its President and CEO Marc Hertz's participation in a Virtual Investor CEO Connect segment. During the presentation, Dr. Hertz discussed the company's lead program, GRI-0621, which targets Idiopathic Pulmonary Fibrosis (IPF), a rare chronic progressive fibrosing interstitial lung disease with treatment options.
The company highlighted upcoming milestones, including interim data expected at the beginning of next quarter and topline data in the subsequent quarter. The presentation is now available for viewing online through Virtual Investor's platform.
GRI Bio (NASDAQ: GRI) has reported its financial results for fiscal year 2024 and provided updates on its lead program GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The company anticipates key data readouts in 2025, with interim data expected in Q2 and topline results in Q3 from its Phase 2a biomarker study.
Financial highlights include:
- Net loss of $8.2 million for 2024
- R&D expenses increased to $3.8 million from $3.2 million in 2023
- G&A expenses decreased to $4.5 million from $8.2 million in 2023
- Cash position of $5.0 million as of December 31, 2024
Recent achievements include presenting positive preclinical data showing GRI-0621 reduces inflammatory and fibrotic drivers in IPF, and receiving a European patent for GRI-0803. The company's cash runway is expected to fund operations into Q2 2025.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, has announced regaining compliance with Nasdaq's minimum bid price rule. The company received official notice from Nasdaq on March 10, 2025, confirming its compliance with Listing Rule 5550(a)(2).
GRI Bio (NASDAQ: GRI) has announced a 1-for-17 reverse stock split, effective February 21, 2025, at 4:01 p.m. Eastern Time. The company's common stock will begin trading on a split-adjusted basis on February 24, 2025, under the same ticker symbol 'GRI' but with a new CUSIP number.
The reverse split aims to increase the per share trading price to regain compliance with Nasdaq's minimum bid price requirement. The split will reduce outstanding shares from approximately 8,933,366 to 525,492. Proportional adjustments will be made to exercise and conversion prices of outstanding stock options, warrants, and convertible securities.
No fractional shares will be issued; stockholders will receive cash payments for fractional shares. Stockholders with electronic book-entry shares require no action, while those holding physical certificates will receive instructions from Broadridge Corporate Issuers Solutions for exchanging certificates.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor "Top 5 for '25" On-Demand Conference. The company's CEO, Marc Hertz, Ph.D., presented the top five reasons why investors and industry colleagues should watch GRI Bio in 2025. The presentation is available for viewing on the company's website and through the conference platform.
GRI Bio (NASDAQ: GRI) announced that the European Patent Office will issue a patent on January 16, 2025, covering GRI-0803 and its library of 500+ proprietary compounds. The patent, titled 'Oxygenated Amino- or Ammonium-Containing Sulfonic Acid, Phosphonic Acid and Carboxylic Acid Derivatives and Their Medical Use,' includes coverage of GRI-0803, a novel activator of human type 2 NKT cells being developed for autoimmune disorders, particularly systemic lupus erythematosus (SLE).
The company's preclinical studies showed that type 2 NKT activating molecules inhibited both murine and human iNKT cells, with oral administration inhibiting lupus nephritis and improving survival. While GRI Bio is currently focusing on GRI-0621, which is in Phase 2a trials for IPF with interim data expected in Q1 2025, the GRI-0803 program will continue in 2025 pending additional funding.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, has announced its participation in the Virtual Investor Closing Bell Series.
The event will take place on Thursday, December 12th, 2024 at 4:00 PM ET, featuring CEO Marc Hertz, PhD, who will present a corporate overview and business outlook. The session will include a moderated discussion and a live Q&A segment where investors can submit questions.
A live video webcast will be available on the Events page of GRI Bio's website, with a replay accessible for 90 days following the event.
GRI Bio presented positive preclinical data for GRI-0621, its lead program targeting Idiopathic Pulmonary Fibrosis (IPF), at the 8th Annual Antifibrotic Drug Development Summit. The data showed that GRI-0621 reduces inflammation and fibrotic drivers in IPF. Key findings demonstrated increased iNKT cell activity correlating with fibrosis progression, while GRI-0621 administration inhibited pro-inflammatory cytokines and decreased neutrophil accumulation. The company is currently conducting a Phase 2a clinical trial for IPF treatment, with interim data expected in Q1 2025 and topline results in Q2 2025.
GRI Bio reported Q3 2024 financial results and progress on GRI-0621, its lead program for Idiopathic Pulmonary Fibrosis (IPF). The company raised $13.9 million in gross proceeds since early 2024, extending cash runway into mid-Q1 2025. Net loss was $6.3 million for the nine months ended September 30, 2024, with R&D expenses at $2.9 million and G&A expenses at $3.3 million. Cash position stands at $4.7 million. The company expects interim data from Phase 2a biomarker study in Q1 2025 and topline results in Q2 2025.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
